{
  "id": "5c915e51ecadf2e73f00000c",
  "type": "yesno",
  "question": "Can prevnar 13 be used in children?",
  "ideal_answer": "Yes, PCV13 is approved for routine vaccination of all infants as a 4-dose series at age 2, 4, 6, and 12-15 months for children who previously received 1 or more doses of the 7-valent pneumococcal conjugate vaccine (PCV7), and for children with underlying medical conditions that increase their risk for pneumococcal disease or its complications.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22045904"
  ],
  "snippets": [
    {
      "text": "PCV13 is approved for routine vaccination of all infants as a 4-dose series at age 2, 4, 6, and 12-15 months for children who previously received 1 or more doses of the 7-valent pneumococcal conjugate vaccine (PCV7), and for children with underlying medical conditions that increase their risk for pneumococcal disease or its complications. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on published immunogenicity and safety data, as well as the recent recommendations by the ACIP for routine use in infants and indications for high-risk pediatric patients, PCV13 is a revised formulation of pneumococcal vaccine that should be included on pharmacy formularies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To review the immunogenicity, efficacy, and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) for use in pediatric patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}